After 9 European Countries, Thailand Latest To Suspend AstraZeneca Covid Vaccine Over Health Concerns - BEST WEBSITE FOR DAILY POPULAR WORLD TOP NEWS - JTN

Friday, March 12, 2021

After 9 European Countries, Thailand Latest To Suspend AstraZeneca Covid Vaccine Over Health Concerns


<p>Thailand on Friday delayed the use of the AstraZeneca made coronavirus vaccine as a precautionary measure after nine European nations, including Iceland, Denmark, Norway, Bulgaria, Estonia and Latvia, temporarily suspended the jabs over blood clot concerns.</p> <p>The delay was based on the decision made by Denmark, Austria and others as a precaution, said the Thai health officials.</p> <p>Austria while investigating death from coagulation disorders has stopped using a batch of AstraZeneca shots.</p> <p>The other experts, however, stated there have been no reported cases of the vaccine causing blood clots or related problems elsewhere, including in Britain.</p> <p><strong>READ</strong>: <strong><a href="https://ift.tt/3lari63" target="_blank" rel="noopener">After Six Month Hiatus, Chinese App TikTok Banned In Pakistan Again Over Profanity Claims</a></strong></p> <p>Yong Poovorawan, an advisor to Thailand's vaccination program, said the delay, pending an investigation into the cause of the reported side effect, will not have a big impact on the rollout, the Associated Press (AP) reported.</p> <p>Earlier on Thursday, the European Medicines Agency said that there was no indication of the jab causing blood clots and added its benefits continue to outweigh its risks.</p> <p><strong>READ</strong>: <strong><a href="https://ift.tt/3rC6S8w" target="_blank" rel="noopener">First 'Single-Shot' Coronavirus Vaccine By Johnson &amp; Johnson Gets EU Approval</a></strong></p> <p>Aiming to inject 10 million doses a month from June, Thailand plans to cover at least half its population by the end of 2021.</p> <p>Thailand began its vaccination drive earlier in February with an initial 200,000 doses of China's Sinovac and 117,000 doses of AstraZeneca.</p>

No comments:

Post a Comment

Enter your email address:

Delivered by FeedBurner